Cardiac Dimensions has announced the appointment of William T Abraham as chief medical officer.
Abraham will help lead the company’s clinical and regulatory strategies as it advances toward US regulatory approval and continues to expand European commercial sales of the Carillon mitral contour system.
Abraham most recently served as the chief medical officer at V-Wave, where he led the US pivotal trial and played a key role in advancing the company’s transcatheter interatrial shunt therapy, culminating in a significant heart failure-focused acquisition by Johnson & Johnson.
“We are delighted to welcome Dr Abraham to the Cardiac Dimensions leadership team,” said Rick Wypych, president and chief executive officer of Cardiac Dimensions. “Bill’s impact on the heart failure field is unmatched. His input and influence on the Carillon therapy will help drive the success and adoption of this much-needed therapy. In addition, his experience with large-scale clinical trials and regulatory pathways will be instrumental to the completion of our pivotal US landmark study—The EMPOWER trial.”
“I’ve spent my career working to bring novel and impactful therapies to people living with heart failure,” said Abraham. “What drew me to Cardiac Dimensions is the Carillon therapy’s unique position in the heart failure treatment paradigm. It offers a physiologically elegant approach to reducing mitral regurgitation, preserving future treatment options, and modifying the disease process itself. I’m particularly encouraged by the consistent data showing favourable atrial and ventricular remodelling, symptom improvement, and an excellent safety profile—even in patients with proportionate mitral regurgitation who are often excluded from other therapies.”
The Carillon mitral contour system has received CE mark and is available for sale in Europe and other countries that recognise CE mark.
